Abstract
Rationale Incidence rates for pulmonary hypertension using diagnostic data in patients with cardiopulmonary disease are not known.
Objectives To determine incidence rates of, risk factors for, and mortality hazard associated with pulmonary hypertension among patients referred for transthoracic echocardiography
Methods Retrospective cohort study using data from the Veterans Health Administration (1999- 2020) and Vanderbilt University Medical Center (1994-2020). Pulmonary hypertension was defined as pulmonary artery systolic pressure >35mmHg with prevalent cases excluded. Heart failure and chronic obstructive pulmonary disease were the primary exposures of interest. The primary outcome was incident pulmonary hypertension. Secondarily, we examined mortality rate following incident diagnosis.
Measurements and Main Results We identified 245,067 VA patients (94% male, 20% Black) and 117,526 Vanderbilt patients (46% male, 11% Black) without pulmonary hypertension, of whom 38,882 VA patients and 8,061 Vanderbilt patients developed pulmonary hypertension. Only 18-19% of patients with echo-based pulmonary hypertension also had a diagnostic code. Hazard of pulmonary hypertension was 4-fold higher in patients with heart failure and chronic obstructive pulmonary disease compared to patients without either. Mortality rates increased from pulmonary artery systolic pressure of 35mmHg to 45mmHg then plateaued. Independent risk factors for incident pulmonary hypertension included older age, male sex, black race, and cardiometabolic comorbidities.
Conclusions Pulmonary hypertension incidence rates estimated by diagnostic data are higher than code-based rates. Heart failure and chronic obstructive pulmonary disease strongly associate with incident pulmonary hypertension. Pulmonary artery systolic pressure >45mmHg at diagnosis is associated with high mortality. New pulmonary hypertension on echocardiography is an important prognostic sign.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the National Heart Lung and Blood Institute: T32 HL 087738 (Garry), R01 HL 163960 (Brittain), R01 HL 146588 (Brittain, Freiberg), R01 HL 155278 (Brittain); National Institute of Diabetes and Digestive and Kidney Diseases: R01 DK 124845 (Brittain); and US Food and Drug Administration R01 FD 007627 (Brittain). The Veterans Affairs Cohort Study is supported by P01 AA 029545 and U24 AA 020794.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Review Boards of the Tennessee Valley Veterans Affairs (VA) Health Care System, West Haven VA Medical Center, and Vanderbilt University Medical Center gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
All authors participated in data interpretation, critically reviewed the manuscript, and approved the final manuscript submitted for publication.
Support: This work was supported by the National Heart Lung and Blood Institute: T32 HL 087738 (Garry), R01 HL 163960 (Brittain), R01 HL 146588 (Brittain, Freiberg), R01 HL 155278 (Brittain); National Institute of Diabetes and Digestive and Kidney Diseases: R01 DK 124845 (Brittain); and US Food and Drug Administration R01 FD 007627 (Brittain). The Veterans Affairs Cohort Study is supported by P01 AA 029545 and U24 AA 020794.
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
